Biobanks of the Department of Clinical Pathology and Cytology

Name of biobank:

Biobanks of the Department of Clinical Pathology and Cytology, UMAS University Hospital, Malmö.

General Information:

The biobank comprises paraffin blocks of surgical and autopsy tissue samples and corresponding histological slides as well as cytological material consisting of slides of vaginal smears, fine needle aspiration biopsies and exfoliative cytological material. The tissue samples date back until 1944 and most of the cytological samples until 1970. A subunit of the bank constitutes the National Tissue Microarray Centre. This centre is supported by SWEGENE with the purpose to organize and construct tissue microarrays (TMA:s) for high throughput molecular pathology research on various kinds of tumours and other diseases. By linking the TMA.s to long-term and complete clinical follow-up data, prognostic and predictive studies will be facilitated.

Responsible organisation:

Region Skåne.

Responsible principle scientist:

Göran Landberg 
Chief managing responsibility for the banks: Margaretha Grabe-Andersson

Rules for acess:

A document describing the rules and guidelines for an access application will be added shortly. For the time being, please contact Margaretha Grabe-Andersson  (concerning the main tissue bank) or Göran Landberg  (concerning the tissue microarray centre).

Biobank content:

Approximately 2,4 million paraffin blocks of surgical tissue specimens,
1,1 million paraffin blocks of tissue samples from autopsies,
3,8 million histological slides and
1,6 million cytology slides.

At present, the Tissue Microarray Centre includes

1. A consecutive series of all invasive breast cancers (n=600) diagnosed in Malmö between 1988 and 1992.
    
2. All incident breast cancers within the Malmö Diet and Cancer cohort (n=400).
    
3. A subgroup of 600 pre-menopausal primary breast cancers within the nationwide, population-based randomised tamoxifen trial SBII:2.
    
4. 180 primary breast cancers from post-menopausal women included in a similar study.
    
5. A set of 120 extremely well characterized primary breast cancer samples with a clinical follow-up of 10 years. More than 40 relevant tumour biological parameters have been recorded in this material and it is therefore useful for a first screening of a marker in order to identify associations to other gene products.
    
6. 350 renal cell carcinomas (In collaboration with NUS).
    

Attached database:

Yes

Variables in database:

General:
Histopathological data of tumours and other disease entities
Tumour biology: Cell cycle regulatory proteins, key oncogenes, markers of proliferation and apoptosis
Patient age
Hormone therapy
Treatment
Events of recurrent disease/death from disease.
Autopsy findings

Specific (Malmö Diet and Cancer):
Diet – a combination of 1 week menu book

Up to five selected publications:

• Lodén M, Stighall M, Nielsen NH, Östlund H, Roos G, Emdin SO, Landberg G.
  The cyclin D1 high and cyclin E high subgroups of primary breast cancer. Separate pathways in tumourogenesis based on pattern of genetic abnormalities.
  Oncogene 21: 4680-4690, 2002.
   
• Landberg G.
  Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis.
  Adv Cancer Res: 84:35-56, 2002.
   
• Hedberg Y, Ljungberg B, Roos G, Landberg G.
  Aberrant cyclin E and p27 protein content in human renal cell carcinoma.
  Internation J Cancer 102: 601-607, 2002.
   
• Hedberg Y, Ljungberg B, Roos G, Landberg G.
  Expression of cyclin D1, D3 E and p27 in human renal cell carcinoma analysed by tissue micro array.
  British J Cancer 88, 1417-1423, 2003.
   
• Jirström K, Ringberg A, Ferno M, Anagnostaki L, Landberg G.
  Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ indicate that low cyclin D1 is a prognostic factor for local recurrence.
  Preliminary accepted in British J Cancer, 2003.
   

Role in The National Biobanking Programme:

We provide researchers with state-of-the-art population based tissue microarrays with long-term and complete follow-up data on survival and treatment. With the TMA-technology, valuable biobank material will be preserved, allowing high throughput in-situ analyses of various tumours and other diseases with a minimal waste of tissue.